Open Collections

UBC Faculty Research and Publications

New drugs VI Therapeutics Initiative (University of British Columbia)

Description

Therapeutics Letter 36 examines benefits and harms of new drugs rosiglitazone, tolterodine, bupropion, and doxazosin. Conclusions: In patients with type 2 diabetes rosiglitazone improves some surrogate markers and worsens others. Long-term trials are required to know whether this class of drugs reduces morbidity and mortality outcomes. Tolterodine and oxybutynin have similar but limited efficacy in patients with overactive bladder symptoms. Dry mouth is a common side effect and occurs more frequently with oxybutynin (78%) than with tolterodine (40%). Bupropion has antidepressant and smoking cessation effects through a unique mechanism of action. The adverse effect profile is different from other antidepressants and includes convulsions and serious allergic reactions. Doxazosin and other alpha-blockers (terazosin, Hytrin® and prazosin, Minipress®) should not be used as first-line drugs in the management of elevated blood pressure.

Item Metadata

Title
New drugs VI
Alternate Title
Therapeutics Letter 36
Creator
Therapeutics Initiative (University of British Columbia)
Date Issued
2000-08
Description
Therapeutics Letter 36 examines benefits and harms of new drugs rosiglitazone, tolterodine, bupropion, and doxazosin. Conclusions: In patients with type 2 diabetes rosiglitazone improves some surrogate markers and worsens others. Long-term trials are required to know whether this class of drugs reduces morbidity and mortality outcomes. Tolterodine and oxybutynin have similar but limited efficacy in patients with overactive bladder symptoms. Dry mouth is a common side effect and occurs more frequently with oxybutynin (78%) than with tolterodine (40%). Bupropion has antidepressant and smoking cessation effects through a unique mechanism of action. The adverse effect profile is different from other antidepressants and includes convulsions and serious allergic reactions. Doxazosin and other alpha-blockers (terazosin, Hytrin® and prazosin, Minipress®) should not be used as first-line drugs in the management of elevated blood pressure.
Subject
Antidepressive Agents; Bupropion; Diabetes Mellitus, Type 2; Doxazosin; Drug-Related Side Effects and Adverse Reactions; Morbidity; Rosiglitazone; Tolterodine Tartrate; Urinary Bladder, Overactive
Genre
Other
Type
Text
Language
eng
Notes
The UBC TI is funded by the BC Ministry of Health to provide evidence-based information about drug therapy. We neither formulate nor adjudicate provincial drug policies.
Date Available
2023-06-20
Provider
Vancouver : University of British Columbia Library
Rights
Attribution-NonCommercial-NoDerivatives 4.0 International
DOI
10.14288/1.0433615
URI
http://hdl.handle.net/2429/85025
Affiliation
Medicine, Faculty of; Anesthesiology, Pharmacology and Therapeutics, Department of
Peer Review Status
Reviewed
Scholarly Level
Faculty; Researcher
Rights URI
http://creativecommons.org/licenses/by-nc-nd/4.0/
Aggregated Source Repository
DSpace

Item Media

Item Citations and Data

Rights

Attribution-NonCommercial-NoDerivatives 4.0 International